Pitfalls and artifacts in the interpretation of oncologic PET/CT of the chest

Meirelles, Gustavo de Souza Portes; Capobianco, Júlia; Oliveira, Marco Antônio Condé de

doi:10.1590/0100-3984.2015.0194

Cited by 7 publications

(5 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reports also indicate that PET with 18 F-FDG has potential as a screening method for cancer and can detect new malignant tumors that other imaging methods fail to detect in asymptomatic individuals ( 24 , 25 ) . The PET/CT combination is a promising hybrid imaging modality that is being used routinely in different clinical situations ( 26 - 29 ) , because it allows precise integration of metabolic PET images with high-quality CT images in an acquisition that goes from the top of the head to the upper thigh ( 19 ) . FDG is a glucose analog used as a marker with fluorine-18, a positron-emitting radioisotope, which allows the study of the glucose metabolism because of its higher uptake by tissues with increased glycolysis.…”

Section: Discussionmentioning

confidence: 99%

Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy

et al. 2019

View full text Add to dashboard Cite

Objective: To evaluate the imaging findings of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and computed tomography (CT) in patients with additional primary tumors, correlating the results with those of the method used in order to elucidate the diagnosis and of the pathology reports. Materials and Methods: We retrospectively analyzed the medical records, pathology reports and images of 11 patients who underwent CT, 18F-FDG PET/CT, or both. We included patients with at least two tumors, with confirmed distinct histopathological profiles, at different sites. Patients in whom there was no diagnostic confirmation were excluded, as were those in whom the additional lesion was suspected of being a metastasis of the first. Results: New primary malignancies were identified in 11 patients, one new tumor being found in 10 and two new tumors being found in 1. The confirmed sites of the additional malignancies were the lung, kidney, prostate, jejunum, and breast. Single or multiple percutaneous biopsies were performed in 10 patients, and 1 patient underwent a surgical procedure for diagnostic and therapeutic purposes. The tumors were metachronous in 6 cases and synchronous in 5. Conclusion: CT and 18F-FDG PET-CT combined with multiple percutaneous biopsy could facilitate the diagnosis of additional lesions, thus optimizing the treatment and follow-up of the affected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Several studies indicated that the mean SUV and SUV max differ according to histologic subtypes of lung cancer. In particular, it has been reported that the SUV max of carcinoid tumors and BAC are low ( 10 , 11 ). Vesselle et al ( 12 ) found that the SUV max of BAC was lower than all other subtypes, and that non-BAC adenocarcinomas had lower SUV max values than SCC.…”

Section: Discussionmentioning

confidence: 99%

The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning

Budak

Çok

Akgün

2018

Mirt

View full text Add to dashboard Cite

Objective:Lung cancer is the most common cause of cancer-related death throughout the world, and the correct choice of treatment based on early diagnosis and staging increases the chance of survival. The present study aims to investigate the contribution of fluorine 18-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG PET/CT) to the management of lung cancer.Methods:In this study, 50 patients who underwent 18F-FDG PET/CT for lung cancer diagnosis and staging between February 2012 and February 2014 were included. The maximum standardized uptake value (SUVmax) of the primary lung lesion along with other findings of 18F-FDG PET/CT and the results of histopathologic and conventional examinations were evaluated retrospectively. The mean survival time of patients was determined, and the findings were compared by using statistical methods.Results:Histopathologic examinations revealed 51 lung cancers in 50 patients. The sensitivity, accuracy and positive predictive value of 18F-FDG PET/CT in detecting primary malignancy were 94%, 94%, 100%, respectively. Adenocarcinoma (n=23, 16.8±13.5) and squamous cell carcinoma (n=15, 17.9±5.6) did not differ significantly regarding their mean SUVmax values (p=0.2). A statistically significant positive correlation (r=0.4) was identified between tumor size and SUVmax value for 51 tumors (p=0.002). The 18F-FDG PET/CT result was true negative in nine, false positive in six, true positive in two, and false negative in four patients who underwent histopathologic evaluation of their lymph nodes. The 18F-FDG PET/CT changed treatment planning in 34% of the patients. No significant relationship was identified between SUVmax value of the tumor and patient survival in patients (p=0.118).Conclusion:The present study concluded that PET/CT was an efficient method in the diagnosis and staging of lung cancer since it provided useful information in addition to conventional methods. It was also observed that PET/CT scanning resulted in a change in therapeutic plans in the majority of patients. However, there was no statistically significant relationship between survival and the SUVmax of the primary mass.

show abstract

“…With regards to radiomics, feature reproducibility is of utmost importance, considering the varying image acquisition (including the highly variable CT protocols and slice thickness), preprocessing, and segmentation [86,87]. PET/CT scan undeniably provides a vast amount of imaging data and parametric information, yet it can be correlated with pitfalls and/or artifacts, while it remains more expensive and difficult from a technical requirement perspective [88]. The absence of universal consensus on the optimal threshold for LC radiomics should also be considered [89].…”

Section: Discussionmentioning

confidence: 99%

Artificial Intelligence-Based Treatment Decisions: A New Era for NSCLC

Fiste,

Gkiozos,

Charpidou

et al. 2024

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related mortality among women and men, in developed countries, despite the public health interventions including tobacco-free campaigns, screening and early detection methods, recent therapeutic advances, and ongoing intense research on novel antineoplastic modalities. Targeting oncogenic driver mutations and immune checkpoint inhibition has indeed revolutionized NSCLC treatment, yet there still remains the unmet need for robust and standardized predictive biomarkers to accurately inform clinical decisions. Artificial intelligence (AI) represents the computer-based science concerned with large datasets for complex problem-solving. Its concept has brought a paradigm shift in oncology considering its immense potential for improved diagnosis, treatment guidance, and prognosis. In this review, we present the current state of AI-driven applications on NSCLC management, with a particular focus on radiomics and pathomics, and critically discuss both the existing limitations and future directions in this field. The thoracic oncology community should not be discouraged by the likely long road of AI implementation into daily clinical practice, as its transformative impact on personalized treatment approaches is undeniable.

show abstract

Pitfalls and artifacts in the interpretation of oncologic PET/CT of the chest

Cited by 7 publications

References 18 publications

Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy

Detection of additional primary malignancies: the role of CT and PET/CT combined with multiple percutaneous biopsy

The Contribution of Fluorine 18F-FDG PET/CT to Lung Cancer Diagnosis, Staging and Treatment Planning

Artificial Intelligence-Based Treatment Decisions: A New Era for NSCLC

Contact Info

Product

Resources

About